Transaction Information
Palisade Bio, Inc. (Nasdaq: PALI) announced that it has closed its private placement with an institutional investor for the purchase of shares of common stock (or certain pre-funded warrants in lieu thereof) and warrants for gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company.
Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering.
The company intends to use the net proceeds from the offering for the continued development of its lead asset, PALI-2108, and for working capital and general corporate purposes
About Palisade Bio
Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier. For more information, please go to www.palisadebio.com.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.